Reduction of infarct size following coronary occlusion.
D000693:Anaerobiosis; D000818:Animals; D001243:Assisted Circulation; D003331:Coronary Vessels / Q000473:pathology*; D003402:Creatine Kinase / Q000378:metabolism; D004562:Electrocardiography; D005947:Glucose / Q000627:therapeutic use; D006019:Glycolysis; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D006854:Hydrocortisone / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D007511:Ischemia; D007545:Isoproterenol / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D009206:Myocardium / Q000378:metabolism; D009336:Necrosis; D010101:Oxygen Consumption; D010477:Perfusion; D011188:Potassium / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use
D007328:Insulin; D011433:Propranolol; D003402:Creatine Kinase; D006821:Hyaluronoglucosaminidase; D005947:Glucose; D007545:Isoproterenol; D011188:Potassium; D006854:Hydrocortisone